Review



bcl2 inhibitor abt 737  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    TargetMol bcl2 inhibitor abt 737
    Bcl2 Inhibitor Abt 737, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitors+abt+737/AMG319/pm41946423-63-42-45
    Average 94 stars, based on 1 article reviews
    bcl2 inhibitor abt 737 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    other:

    Article Title: Endocytosis triggers V-ATPase-SYK-mediated priming of cGAS activation and innate immune response.
    Article Snippet: The inhibitors ABT-737 (HY-50907), Q-VD-OPh (HY-12305), PRT062607 (HY15322), BAY 61-3606 dihydrochloride (HY-14985), Vecabrutinib (HY-109078), BMS-509744 (HY-11092), PRN1371 (HY-101768), BLZ945 (HY-12768), AG 1295 (HY-101957), RU.521 (HY-114180), STING-IN-3 (HY-138683), Baf-A1 (HY-100558), EN6 (HY-128892), and zalcitabine (HY-17392) were purchased from MCE; AZD4547 (T1948), FIIN-2 (T6836), and Orantinib (T6184), CP673451 (T6091) were purchased from Target Mol.

    Article Title: Endocytosis triggers V-ATPase-SYK–mediated priming of cGAS activation and innate immune response
    Article Snippet: The inhibitors ABT-737 (HY-50907), Q-VD-OPh (HY-12305), PRT062607 (HY-15322), BAY 61-3606 dihydrochloride (HY-14985), Vecabrutinib (HY-109078), BMS-509744 (HY-11092), PRN1371 (HY-101768), BLZ945 (HY-12768), AG 1295 (HY-101957), RU.521 (HY-114180), STING-IN-3 (HY-138683), Baf-A1 (HY-100558), EN6 (HY-128892), and zalcitabine (HY-17392) were purchased from MCE; AZD4547 (T1948), FIIN-2 (T6836), and Orantinib (T6184), CP673451 (T6091) were purchased from Target Mol.



    Similar Products

    94
    TargetMol bcl2 inhibitor abt 737
    Bcl2 Inhibitor Abt 737, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitors+abt+737/AMG319/pm41946423-63-42-45
    Average 94 stars, based on 1 article reviews
    bcl2 inhibitor abt 737 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    96
    MedChemExpress mcl1 inhibitor s63458
    CMT2A variants of MFN2 cause apoptotic cell death. (A) Western blot analysis (upper panel) and quantification (lower panel) of HeLa WT cells or 2KO cells stably expressing FLAG-tagged K357N variant of MFN2, untreated or treated with Act D (1 µM, 6 h), with or without ZVAD (20 µM, 6 h), as indicated, immunoblotted with anti-PARP1 and anti-MFN2 antibodies. Staining of total protein with Ponceau S (PoS) was used as loading control. Bars represent the mean±s.d. intensity of cleaved PARP1, normalized to the PoS staining and shown relative to untreated K357N cells ( n =5 biological repeats). Individual values of each experiment are plotted as open and filled circles, squares, triangles, diamonds and hexagons. One-way ANOVA with Tukey's post-hoc test was applied. P values from left to right: ** P =0.0091; * P =0.0205; **** P <0.0001; ** P =0.0060. (B) Annexin V 568 fluorescence, measured by the Incucyte live imaging system over 48 h and plotted relative to timepoint zero, of HeLa WT or 2KO cells stably expressing FLAG-tagged K357N variant of MFN2, either untreated or treated with ABT+S (BH3 mimetic ABT-737 and the <t>MCL1</t> inhibitor S63845 , 0.1 µM, 48 h) for apoptosis induction, and in presence or absence of ZVAD (20 µM, 48 h) for inhibition of caspases, as indicated. Values represent the mean±s.d. intensity per object count of three technical replicates each from three biological replicates. (C) Annexin V 568 fluorescence, analysed as in B, of HeLa 2KO cells transiently transfected with WT MFN2, MFN2 R364Q, MFN2 R707W or MFN2 K357N, either untreated or treated with ABT+S (0.1 µM, 24 h). Values represent the mean intensity per object count of a single technical replicate each from three biological replicates.
    Mcl1 Inhibitor S63458, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitors+abt+737/ABT-737/pmc12516130-228-18-21
    Average 96 stars, based on 1 article reviews
    mcl1 inhibitor s63458 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Selleck Chemicals caspase inhibitor zvad fmk
    SARM1 promotes apoptotic cell death. ( A ) Neuro-2a cells show defective apoptosis. WT Neuro-2a cells and two single-cell derived Sarm1 KO lines (KO-1 and KO-2, generated by CRISPR-Cas9 mediated targeting) were treated either with DMSO or with TNF-α (20 ng/mL, TNF) combined with cycloheximide (10 µg/mL, CHX) for 16 h. Percent cell survival was determined by measuring total ATP level and normalizing to control (DMSO) treatment. Data are from three biological replicates. The two KO lines were verified by Western blotting of SARM1 ( Left ) using a monoclonal antibody targeting the amino terminus of SARM1 (clone 10G2, SI Appendix , Fig. S4 ). Tubulin Western blot was used as loading control. Western blot data shown are representative of three independent experiments. ( B ) <t>Caspase-3/7</t> activity (i.e., DEVDase activity) following TNF and CHX cotreatment was measured using the caspase-glo kit from Promega. AU, arbitrary units. Data are from three biological replicates. ( C and D ) effect of SARM1 on apoptosis of macrophages and T cells. ( C ) primary bone marrow derived macrophages were treated with DMSO or TNF (10 ng/mL) and CHX (10 µg/mL) for 7 h. ( D ) primary T cells were treated with ABT-737 (1 µM) for 23 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. ( E ) SARM1 expression sensitizes HeLa cells to apoptosis. HeLa cells stably expressing GFP (HeLa+GFP) and HeLa cells stably expressing SARM1 (HeLa+SARM1) were treated with TNF+CHX for 18 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. SARM1 expression was confirmed by Western blot ( Left ). A portion of the stain free gel image was used as an internal loading control. Western blot data shown are representative of three independent experiments. ( F and G ) Sarm1 KO blocks anti-NGF-induced axon degeneration in the presence of caspase inhibitor. ( F ) Representative images of WT and Sarm1 KO DRG cultures (7 d in vitro, DIV) treated with DMSO, anti-NGF, or anti-NGF together <t>with</t> <t>zVAD-FMK</t> (100 µM, zVAD) for 22 h. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( G ) Axon degeneration percentage of ( F ) was quantified and shown in the bar graphs. Data are from three biological replicates. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.
    Caspase Inhibitor Zvad Fmk, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitors+abt+737/ABT-737/pmc12846840-163-3-9
    Average 96 stars, based on 1 article reviews
    caspase inhibitor zvad fmk - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Selleck Chemicals inhibitors abt 737
    SARM1 promotes apoptotic cell death. ( A ) Neuro-2a cells show defective apoptosis. WT Neuro-2a cells and two single-cell derived Sarm1 KO lines (KO-1 and KO-2, generated by CRISPR-Cas9 mediated targeting) were treated either with DMSO or with TNF-α (20 ng/mL, TNF) combined with cycloheximide (10 µg/mL, CHX) for 16 h. Percent cell survival was determined by measuring total ATP level and normalizing to control (DMSO) treatment. Data are from three biological replicates. The two KO lines were verified by Western blotting of SARM1 ( Left ) using a monoclonal antibody targeting the amino terminus of SARM1 (clone 10G2, SI Appendix , Fig. S4 ). Tubulin Western blot was used as loading control. Western blot data shown are representative of three independent experiments. ( B ) <t>Caspase-3/7</t> activity (i.e., DEVDase activity) following TNF and CHX cotreatment was measured using the caspase-glo kit from Promega. AU, arbitrary units. Data are from three biological replicates. ( C and D ) effect of SARM1 on apoptosis of macrophages and T cells. ( C ) primary bone marrow derived macrophages were treated with DMSO or TNF (10 ng/mL) and CHX (10 µg/mL) for 7 h. ( D ) primary T cells were treated with ABT-737 (1 µM) for 23 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. ( E ) SARM1 expression sensitizes HeLa cells to apoptosis. HeLa cells stably expressing GFP (HeLa+GFP) and HeLa cells stably expressing SARM1 (HeLa+SARM1) were treated with TNF+CHX for 18 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. SARM1 expression was confirmed by Western blot ( Left ). A portion of the stain free gel image was used as an internal loading control. Western blot data shown are representative of three independent experiments. ( F and G ) Sarm1 KO blocks anti-NGF-induced axon degeneration in the presence of caspase inhibitor. ( F ) Representative images of WT and Sarm1 KO DRG cultures (7 d in vitro, DIV) treated with DMSO, anti-NGF, or anti-NGF together <t>with</t> <t>zVAD-FMK</t> (100 µM, zVAD) for 22 h. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( G ) Axon degeneration percentage of ( F ) was quantified and shown in the bar graphs. Data are from three biological replicates. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.
    Inhibitors Abt 737, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitors+abt+737/ABT-737/pm41326406-259-4-6
    Average 96 stars, based on 1 article reviews
    inhibitors abt 737 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    90
    Abbott Laboratories bcl-2 inhibitor abt-737
    SARM1 promotes apoptotic cell death. ( A ) Neuro-2a cells show defective apoptosis. WT Neuro-2a cells and two single-cell derived Sarm1 KO lines (KO-1 and KO-2, generated by CRISPR-Cas9 mediated targeting) were treated either with DMSO or with TNF-α (20 ng/mL, TNF) combined with cycloheximide (10 µg/mL, CHX) for 16 h. Percent cell survival was determined by measuring total ATP level and normalizing to control (DMSO) treatment. Data are from three biological replicates. The two KO lines were verified by Western blotting of SARM1 ( Left ) using a monoclonal antibody targeting the amino terminus of SARM1 (clone 10G2, SI Appendix , Fig. S4 ). Tubulin Western blot was used as loading control. Western blot data shown are representative of three independent experiments. ( B ) <t>Caspase-3/7</t> activity (i.e., DEVDase activity) following TNF and CHX cotreatment was measured using the caspase-glo kit from Promega. AU, arbitrary units. Data are from three biological replicates. ( C and D ) effect of SARM1 on apoptosis of macrophages and T cells. ( C ) primary bone marrow derived macrophages were treated with DMSO or TNF (10 ng/mL) and CHX (10 µg/mL) for 7 h. ( D ) primary T cells were treated with ABT-737 (1 µM) for 23 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. ( E ) SARM1 expression sensitizes HeLa cells to apoptosis. HeLa cells stably expressing GFP (HeLa+GFP) and HeLa cells stably expressing SARM1 (HeLa+SARM1) were treated with TNF+CHX for 18 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. SARM1 expression was confirmed by Western blot ( Left ). A portion of the stain free gel image was used as an internal loading control. Western blot data shown are representative of three independent experiments. ( F and G ) Sarm1 KO blocks anti-NGF-induced axon degeneration in the presence of caspase inhibitor. ( F ) Representative images of WT and Sarm1 KO DRG cultures (7 d in vitro, DIV) treated with DMSO, anti-NGF, or anti-NGF together <t>with</t> <t>zVAD-FMK</t> (100 µM, zVAD) for 22 h. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( G ) Axon degeneration percentage of ( F ) was quantified and shown in the bar graphs. Data are from three biological replicates. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.
    Bcl 2 Inhibitor Abt 737, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitors+abt+737/abt+263/pm40427140-49-63-68
    Average 90 stars, based on 1 article reviews
    bcl-2 inhibitor abt-737 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    93
    Tocris 186 bcl2 inhibitor abt 737
    SARM1 promotes apoptotic cell death. ( A ) Neuro-2a cells show defective apoptosis. WT Neuro-2a cells and two single-cell derived Sarm1 KO lines (KO-1 and KO-2, generated by CRISPR-Cas9 mediated targeting) were treated either with DMSO or with TNF-α (20 ng/mL, TNF) combined with cycloheximide (10 µg/mL, CHX) for 16 h. Percent cell survival was determined by measuring total ATP level and normalizing to control (DMSO) treatment. Data are from three biological replicates. The two KO lines were verified by Western blotting of SARM1 ( Left ) using a monoclonal antibody targeting the amino terminus of SARM1 (clone 10G2, SI Appendix , Fig. S4 ). Tubulin Western blot was used as loading control. Western blot data shown are representative of three independent experiments. ( B ) <t>Caspase-3/7</t> activity (i.e., DEVDase activity) following TNF and CHX cotreatment was measured using the caspase-glo kit from Promega. AU, arbitrary units. Data are from three biological replicates. ( C and D ) effect of SARM1 on apoptosis of macrophages and T cells. ( C ) primary bone marrow derived macrophages were treated with DMSO or TNF (10 ng/mL) and CHX (10 µg/mL) for 7 h. ( D ) primary T cells were treated with ABT-737 (1 µM) for 23 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. ( E ) SARM1 expression sensitizes HeLa cells to apoptosis. HeLa cells stably expressing GFP (HeLa+GFP) and HeLa cells stably expressing SARM1 (HeLa+SARM1) were treated with TNF+CHX for 18 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. SARM1 expression was confirmed by Western blot ( Left ). A portion of the stain free gel image was used as an internal loading control. Western blot data shown are representative of three independent experiments. ( F and G ) Sarm1 KO blocks anti-NGF-induced axon degeneration in the presence of caspase inhibitor. ( F ) Representative images of WT and Sarm1 KO DRG cultures (7 d in vitro, DIV) treated with DMSO, anti-NGF, or anti-NGF together <t>with</t> <t>zVAD-FMK</t> (100 µM, zVAD) for 22 h. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( G ) Axon degeneration percentage of ( F ) was quantified and shown in the bar graphs. Data are from three biological replicates. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.
    186 Bcl2 Inhibitor Abt 737, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitors+abt+737/Z-VAD-FMK/pm40024310-69-11-15
    Average 93 stars, based on 1 article reviews
    186 bcl2 inhibitor abt 737 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    94
    TargetMol bcl xl inhibitor abt 737
    SARM1 promotes apoptotic cell death. ( A ) Neuro-2a cells show defective apoptosis. WT Neuro-2a cells and two single-cell derived Sarm1 KO lines (KO-1 and KO-2, generated by CRISPR-Cas9 mediated targeting) were treated either with DMSO or with TNF-α (20 ng/mL, TNF) combined with cycloheximide (10 µg/mL, CHX) for 16 h. Percent cell survival was determined by measuring total ATP level and normalizing to control (DMSO) treatment. Data are from three biological replicates. The two KO lines were verified by Western blotting of SARM1 ( Left ) using a monoclonal antibody targeting the amino terminus of SARM1 (clone 10G2, SI Appendix , Fig. S4 ). Tubulin Western blot was used as loading control. Western blot data shown are representative of three independent experiments. ( B ) <t>Caspase-3/7</t> activity (i.e., DEVDase activity) following TNF and CHX cotreatment was measured using the caspase-glo kit from Promega. AU, arbitrary units. Data are from three biological replicates. ( C and D ) effect of SARM1 on apoptosis of macrophages and T cells. ( C ) primary bone marrow derived macrophages were treated with DMSO or TNF (10 ng/mL) and CHX (10 µg/mL) for 7 h. ( D ) primary T cells were treated with ABT-737 (1 µM) for 23 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. ( E ) SARM1 expression sensitizes HeLa cells to apoptosis. HeLa cells stably expressing GFP (HeLa+GFP) and HeLa cells stably expressing SARM1 (HeLa+SARM1) were treated with TNF+CHX for 18 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. SARM1 expression was confirmed by Western blot ( Left ). A portion of the stain free gel image was used as an internal loading control. Western blot data shown are representative of three independent experiments. ( F and G ) Sarm1 KO blocks anti-NGF-induced axon degeneration in the presence of caspase inhibitor. ( F ) Representative images of WT and Sarm1 KO DRG cultures (7 d in vitro, DIV) treated with DMSO, anti-NGF, or anti-NGF together <t>with</t> <t>zVAD-FMK</t> (100 µM, zVAD) for 22 h. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( G ) Axon degeneration percentage of ( F ) was quantified and shown in the bar graphs. Data are from three biological replicates. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.
    Bcl Xl Inhibitor Abt 737, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitors+abt+737/ABT737/pmc11930375-33-0-4
    Average 94 stars, based on 1 article reviews
    bcl xl inhibitor abt 737 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    TargetMol t2125 bcl xl inhibitor abt 737 targetmol t2099 anti pdl1 bio x cell bx be0101 anti ctla4 bio x cell bx be0131
    SARM1 promotes apoptotic cell death. ( A ) Neuro-2a cells show defective apoptosis. WT Neuro-2a cells and two single-cell derived Sarm1 KO lines (KO-1 and KO-2, generated by CRISPR-Cas9 mediated targeting) were treated either with DMSO or with TNF-α (20 ng/mL, TNF) combined with cycloheximide (10 µg/mL, CHX) for 16 h. Percent cell survival was determined by measuring total ATP level and normalizing to control (DMSO) treatment. Data are from three biological replicates. The two KO lines were verified by Western blotting of SARM1 ( Left ) using a monoclonal antibody targeting the amino terminus of SARM1 (clone 10G2, SI Appendix , Fig. S4 ). Tubulin Western blot was used as loading control. Western blot data shown are representative of three independent experiments. ( B ) <t>Caspase-3/7</t> activity (i.e., DEVDase activity) following TNF and CHX cotreatment was measured using the caspase-glo kit from Promega. AU, arbitrary units. Data are from three biological replicates. ( C and D ) effect of SARM1 on apoptosis of macrophages and T cells. ( C ) primary bone marrow derived macrophages were treated with DMSO or TNF (10 ng/mL) and CHX (10 µg/mL) for 7 h. ( D ) primary T cells were treated with ABT-737 (1 µM) for 23 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. ( E ) SARM1 expression sensitizes HeLa cells to apoptosis. HeLa cells stably expressing GFP (HeLa+GFP) and HeLa cells stably expressing SARM1 (HeLa+SARM1) were treated with TNF+CHX for 18 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. SARM1 expression was confirmed by Western blot ( Left ). A portion of the stain free gel image was used as an internal loading control. Western blot data shown are representative of three independent experiments. ( F and G ) Sarm1 KO blocks anti-NGF-induced axon degeneration in the presence of caspase inhibitor. ( F ) Representative images of WT and Sarm1 KO DRG cultures (7 d in vitro, DIV) treated with DMSO, anti-NGF, or anti-NGF together <t>with</t> <t>zVAD-FMK</t> (100 µM, zVAD) for 22 h. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( G ) Axon degeneration percentage of ( F ) was quantified and shown in the bar graphs. Data are from three biological replicates. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.
    T2125 Bcl Xl Inhibitor Abt 737 Targetmol T2099 Anti Pdl1 Bio X Cell Bx Be0101 Anti Ctla4 Bio X Cell Bx Be0131, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitors+abt+737/Trametinib/10__1016_slash_j__isci__2025__112071-314-207-211
    Average 94 stars, based on 1 article reviews
    t2125 bcl xl inhibitor abt 737 targetmol t2099 anti pdl1 bio x cell bx be0101 anti ctla4 bio x cell bx be0131 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    96
    MedChemExpress bcl 2 inhibitor abt737
    SARM1 promotes apoptotic cell death. ( A ) Neuro-2a cells show defective apoptosis. WT Neuro-2a cells and two single-cell derived Sarm1 KO lines (KO-1 and KO-2, generated by CRISPR-Cas9 mediated targeting) were treated either with DMSO or with TNF-α (20 ng/mL, TNF) combined with cycloheximide (10 µg/mL, CHX) for 16 h. Percent cell survival was determined by measuring total ATP level and normalizing to control (DMSO) treatment. Data are from three biological replicates. The two KO lines were verified by Western blotting of SARM1 ( Left ) using a monoclonal antibody targeting the amino terminus of SARM1 (clone 10G2, SI Appendix , Fig. S4 ). Tubulin Western blot was used as loading control. Western blot data shown are representative of three independent experiments. ( B ) <t>Caspase-3/7</t> activity (i.e., DEVDase activity) following TNF and CHX cotreatment was measured using the caspase-glo kit from Promega. AU, arbitrary units. Data are from three biological replicates. ( C and D ) effect of SARM1 on apoptosis of macrophages and T cells. ( C ) primary bone marrow derived macrophages were treated with DMSO or TNF (10 ng/mL) and CHX (10 µg/mL) for 7 h. ( D ) primary T cells were treated with ABT-737 (1 µM) for 23 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. ( E ) SARM1 expression sensitizes HeLa cells to apoptosis. HeLa cells stably expressing GFP (HeLa+GFP) and HeLa cells stably expressing SARM1 (HeLa+SARM1) were treated with TNF+CHX for 18 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. SARM1 expression was confirmed by Western blot ( Left ). A portion of the stain free gel image was used as an internal loading control. Western blot data shown are representative of three independent experiments. ( F and G ) Sarm1 KO blocks anti-NGF-induced axon degeneration in the presence of caspase inhibitor. ( F ) Representative images of WT and Sarm1 KO DRG cultures (7 d in vitro, DIV) treated with DMSO, anti-NGF, or anti-NGF together <t>with</t> <t>zVAD-FMK</t> (100 µM, zVAD) for 22 h. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( G ) Axon degeneration percentage of ( F ) was quantified and shown in the bar graphs. Data are from three biological replicates. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.
    Bcl 2 Inhibitor Abt737, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitors+abt+737/ABT-737/10__1016_slash_j__vetmic__2024__110298-52-7-40
    Average 96 stars, based on 1 article reviews
    bcl 2 inhibitor abt737 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    CMT2A variants of MFN2 cause apoptotic cell death. (A) Western blot analysis (upper panel) and quantification (lower panel) of HeLa WT cells or 2KO cells stably expressing FLAG-tagged K357N variant of MFN2, untreated or treated with Act D (1 µM, 6 h), with or without ZVAD (20 µM, 6 h), as indicated, immunoblotted with anti-PARP1 and anti-MFN2 antibodies. Staining of total protein with Ponceau S (PoS) was used as loading control. Bars represent the mean±s.d. intensity of cleaved PARP1, normalized to the PoS staining and shown relative to untreated K357N cells ( n =5 biological repeats). Individual values of each experiment are plotted as open and filled circles, squares, triangles, diamonds and hexagons. One-way ANOVA with Tukey's post-hoc test was applied. P values from left to right: ** P =0.0091; * P =0.0205; **** P <0.0001; ** P =0.0060. (B) Annexin V 568 fluorescence, measured by the Incucyte live imaging system over 48 h and plotted relative to timepoint zero, of HeLa WT or 2KO cells stably expressing FLAG-tagged K357N variant of MFN2, either untreated or treated with ABT+S (BH3 mimetic ABT-737 and the MCL1 inhibitor S63845 , 0.1 µM, 48 h) for apoptosis induction, and in presence or absence of ZVAD (20 µM, 48 h) for inhibition of caspases, as indicated. Values represent the mean±s.d. intensity per object count of three technical replicates each from three biological replicates. (C) Annexin V 568 fluorescence, analysed as in B, of HeLa 2KO cells transiently transfected with WT MFN2, MFN2 R364Q, MFN2 R707W or MFN2 K357N, either untreated or treated with ABT+S (0.1 µM, 24 h). Values represent the mean intensity per object count of a single technical replicate each from three biological replicates.

    Journal: Journal of Cell Science

    Article Title: Charcot–Marie–Tooth type 2A variants of mitofusin 2 sensitize cells to apoptotic cell death

    doi: 10.1242/jcs.263691

    Figure Lengend Snippet: CMT2A variants of MFN2 cause apoptotic cell death. (A) Western blot analysis (upper panel) and quantification (lower panel) of HeLa WT cells or 2KO cells stably expressing FLAG-tagged K357N variant of MFN2, untreated or treated with Act D (1 µM, 6 h), with or without ZVAD (20 µM, 6 h), as indicated, immunoblotted with anti-PARP1 and anti-MFN2 antibodies. Staining of total protein with Ponceau S (PoS) was used as loading control. Bars represent the mean±s.d. intensity of cleaved PARP1, normalized to the PoS staining and shown relative to untreated K357N cells ( n =5 biological repeats). Individual values of each experiment are plotted as open and filled circles, squares, triangles, diamonds and hexagons. One-way ANOVA with Tukey's post-hoc test was applied. P values from left to right: ** P =0.0091; * P =0.0205; **** P <0.0001; ** P =0.0060. (B) Annexin V 568 fluorescence, measured by the Incucyte live imaging system over 48 h and plotted relative to timepoint zero, of HeLa WT or 2KO cells stably expressing FLAG-tagged K357N variant of MFN2, either untreated or treated with ABT+S (BH3 mimetic ABT-737 and the MCL1 inhibitor S63845 , 0.1 µM, 48 h) for apoptosis induction, and in presence or absence of ZVAD (20 µM, 48 h) for inhibition of caspases, as indicated. Values represent the mean±s.d. intensity per object count of three technical replicates each from three biological replicates. (C) Annexin V 568 fluorescence, analysed as in B, of HeLa 2KO cells transiently transfected with WT MFN2, MFN2 R364Q, MFN2 R707W or MFN2 K357N, either untreated or treated with ABT+S (0.1 µM, 24 h). Values represent the mean intensity per object count of a single technical replicate each from three biological replicates.

    Article Snippet: The following chemicals were used for cell culture treatments: actinomyin D (Sigma-Aldrich, Schnelldorf, Germany), ABT-737 (MedChemExpress, Sollentuna, Sweden), MCL1 inhibitor S63458 (MedChemExpress Sollentuna, Sweden), ZVAD-FMK (Hölzel, Köln, Germany), ISR inhibitor (ISRIB) (Merck, Hamburg, Germany), thapsigargin (NEB, Frankfurt am Main, Germany), staurosporine (Sigma-Aldrich, Schnelldorf, Germany).

    Techniques: Western Blot, Stable Transfection, Expressing, Variant Assay, Staining, Control, Fluorescence, Imaging, Inhibition, Transfection

    SARM1 promotes apoptotic cell death. ( A ) Neuro-2a cells show defective apoptosis. WT Neuro-2a cells and two single-cell derived Sarm1 KO lines (KO-1 and KO-2, generated by CRISPR-Cas9 mediated targeting) were treated either with DMSO or with TNF-α (20 ng/mL, TNF) combined with cycloheximide (10 µg/mL, CHX) for 16 h. Percent cell survival was determined by measuring total ATP level and normalizing to control (DMSO) treatment. Data are from three biological replicates. The two KO lines were verified by Western blotting of SARM1 ( Left ) using a monoclonal antibody targeting the amino terminus of SARM1 (clone 10G2, SI Appendix , Fig. S4 ). Tubulin Western blot was used as loading control. Western blot data shown are representative of three independent experiments. ( B ) Caspase-3/7 activity (i.e., DEVDase activity) following TNF and CHX cotreatment was measured using the caspase-glo kit from Promega. AU, arbitrary units. Data are from three biological replicates. ( C and D ) effect of SARM1 on apoptosis of macrophages and T cells. ( C ) primary bone marrow derived macrophages were treated with DMSO or TNF (10 ng/mL) and CHX (10 µg/mL) for 7 h. ( D ) primary T cells were treated with ABT-737 (1 µM) for 23 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. ( E ) SARM1 expression sensitizes HeLa cells to apoptosis. HeLa cells stably expressing GFP (HeLa+GFP) and HeLa cells stably expressing SARM1 (HeLa+SARM1) were treated with TNF+CHX for 18 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. SARM1 expression was confirmed by Western blot ( Left ). A portion of the stain free gel image was used as an internal loading control. Western blot data shown are representative of three independent experiments. ( F and G ) Sarm1 KO blocks anti-NGF-induced axon degeneration in the presence of caspase inhibitor. ( F ) Representative images of WT and Sarm1 KO DRG cultures (7 d in vitro, DIV) treated with DMSO, anti-NGF, or anti-NGF together with zVAD-FMK (100 µM, zVAD) for 22 h. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( G ) Axon degeneration percentage of ( F ) was quantified and shown in the bar graphs. Data are from three biological replicates. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Caspase-3 cleaves and activates the NADase SARM1 to promote apoptosis, linking two cell death mechanisms

    doi: 10.1073/pnas.2528118123

    Figure Lengend Snippet: SARM1 promotes apoptotic cell death. ( A ) Neuro-2a cells show defective apoptosis. WT Neuro-2a cells and two single-cell derived Sarm1 KO lines (KO-1 and KO-2, generated by CRISPR-Cas9 mediated targeting) were treated either with DMSO or with TNF-α (20 ng/mL, TNF) combined with cycloheximide (10 µg/mL, CHX) for 16 h. Percent cell survival was determined by measuring total ATP level and normalizing to control (DMSO) treatment. Data are from three biological replicates. The two KO lines were verified by Western blotting of SARM1 ( Left ) using a monoclonal antibody targeting the amino terminus of SARM1 (clone 10G2, SI Appendix , Fig. S4 ). Tubulin Western blot was used as loading control. Western blot data shown are representative of three independent experiments. ( B ) Caspase-3/7 activity (i.e., DEVDase activity) following TNF and CHX cotreatment was measured using the caspase-glo kit from Promega. AU, arbitrary units. Data are from three biological replicates. ( C and D ) effect of SARM1 on apoptosis of macrophages and T cells. ( C ) primary bone marrow derived macrophages were treated with DMSO or TNF (10 ng/mL) and CHX (10 µg/mL) for 7 h. ( D ) primary T cells were treated with ABT-737 (1 µM) for 23 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. ( E ) SARM1 expression sensitizes HeLa cells to apoptosis. HeLa cells stably expressing GFP (HeLa+GFP) and HeLa cells stably expressing SARM1 (HeLa+SARM1) were treated with TNF+CHX for 18 h. Percent cell survival was determined by measuring total ATP level and normalized to control (DMSO) treatment. Data are from three biological replicates. SARM1 expression was confirmed by Western blot ( Left ). A portion of the stain free gel image was used as an internal loading control. Western blot data shown are representative of three independent experiments. ( F and G ) Sarm1 KO blocks anti-NGF-induced axon degeneration in the presence of caspase inhibitor. ( F ) Representative images of WT and Sarm1 KO DRG cultures (7 d in vitro, DIV) treated with DMSO, anti-NGF, or anti-NGF together with zVAD-FMK (100 µM, zVAD) for 22 h. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( G ) Axon degeneration percentage of ( F ) was quantified and shown in the bar graphs. Data are from three biological replicates. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.

    Article Snippet: ABT-737 and the caspase inhibitor zVAD-FMK were purchased from Selleck Chemicals.

    Techniques: Derivative Assay, Generated, CRISPR, Control, Western Blot, Activity Assay, Expressing, Stable Transfection, Staining, In Vitro

    SARM1 is cleaved by active caspase-3. ( A ) DRG cultures were treated with anti-NGF for 16 h. Western blot of SARM1 protein shows reduction of full-length SARM1 (SARM1 FL) and increase of a band of ~33 kDa. A Sarm1 KO sample was used to demonstrate the specificity of the SARM1 antibody ( Left lane). A portion of the stain free gel image was used as an internal loading control. Data are representative of three independent experiments. ( B ) SARM1 from DRG cultures treated with ABT-737 (10 µM, 6 h) also shows a decrease in full-length SARM1 and increase in the ~33 kDa band. A portion of the stain-free gel image was used as an internal loading control. Data are representative of three independent experiments. ( C ) Western blot of SARM1 from control DRG cultures and following axotomy (6 h) shows that SARM1 is not cleaved during Wallerian degeneration. A portion of the stain free gel image was used as an internal loading control. Data are representative of three independent experiments. ( D ) Neuro-2a cells were treated with DMSO (control) or with TNF+CHX for 18 h to induce apoptosis. As in primary neurons, there is a reduction of full-length SARM1 and increase of a band of ~33 kDa. Both effects are blocked by the pan-caspase inhibitor zVAD. T + C: TNF+CHX, T + C + Z: TNF+CHX+zVAD. (Full Western blot shown in SI Appendix , Fig. S2 ). Tubulin Western blot was used as loading control. Data are representative of three independent experiments. ( E ) In vitro cleavage of recombinant SARM1 by active caspase-3. Purified SARM1 (on beads) was incubated with active caspase-3. Cleavage was determined by protein electrophoresis and Coomassie staining. *HC, anti-Flag antibody heavy chain conjugated on beads, *LC: anti-Flag antibody light chain conjugated on beads. Data are representative of three independent experiments. ( F ) Western blot of the caspase-cleaved SARM1 samples using antibody targeting the N-terminal FLAG tag. Data are representative of three independent experiments. Diagram shows the location of the FLAG tag at the N terminus of SARM1. ( G ) Effect of the SARM1 D314A mutation on caspase-3 cleavage. Recombinant WT SARM1 or SARM1 D314A were incubated with active caspase-3 and cleavage was determined as in E . Data are representative of three independent experiments. ( H ) Effect of SARM1 catalytic mutant on caspase-3 cleavage. Data are representative of three independent experiments.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Caspase-3 cleaves and activates the NADase SARM1 to promote apoptosis, linking two cell death mechanisms

    doi: 10.1073/pnas.2528118123

    Figure Lengend Snippet: SARM1 is cleaved by active caspase-3. ( A ) DRG cultures were treated with anti-NGF for 16 h. Western blot of SARM1 protein shows reduction of full-length SARM1 (SARM1 FL) and increase of a band of ~33 kDa. A Sarm1 KO sample was used to demonstrate the specificity of the SARM1 antibody ( Left lane). A portion of the stain free gel image was used as an internal loading control. Data are representative of three independent experiments. ( B ) SARM1 from DRG cultures treated with ABT-737 (10 µM, 6 h) also shows a decrease in full-length SARM1 and increase in the ~33 kDa band. A portion of the stain-free gel image was used as an internal loading control. Data are representative of three independent experiments. ( C ) Western blot of SARM1 from control DRG cultures and following axotomy (6 h) shows that SARM1 is not cleaved during Wallerian degeneration. A portion of the stain free gel image was used as an internal loading control. Data are representative of three independent experiments. ( D ) Neuro-2a cells were treated with DMSO (control) or with TNF+CHX for 18 h to induce apoptosis. As in primary neurons, there is a reduction of full-length SARM1 and increase of a band of ~33 kDa. Both effects are blocked by the pan-caspase inhibitor zVAD. T + C: TNF+CHX, T + C + Z: TNF+CHX+zVAD. (Full Western blot shown in SI Appendix , Fig. S2 ). Tubulin Western blot was used as loading control. Data are representative of three independent experiments. ( E ) In vitro cleavage of recombinant SARM1 by active caspase-3. Purified SARM1 (on beads) was incubated with active caspase-3. Cleavage was determined by protein electrophoresis and Coomassie staining. *HC, anti-Flag antibody heavy chain conjugated on beads, *LC: anti-Flag antibody light chain conjugated on beads. Data are representative of three independent experiments. ( F ) Western blot of the caspase-cleaved SARM1 samples using antibody targeting the N-terminal FLAG tag. Data are representative of three independent experiments. Diagram shows the location of the FLAG tag at the N terminus of SARM1. ( G ) Effect of the SARM1 D314A mutation on caspase-3 cleavage. Recombinant WT SARM1 or SARM1 D314A were incubated with active caspase-3 and cleavage was determined as in E . Data are representative of three independent experiments. ( H ) Effect of SARM1 catalytic mutant on caspase-3 cleavage. Data are representative of three independent experiments.

    Article Snippet: ABT-737 and the caspase inhibitor zVAD-FMK were purchased from Selleck Chemicals.

    Techniques: Western Blot, Staining, Control, In Vitro, Recombinant, Purification, Incubation, Protein Electrophoresis, FLAG-tag, Mutagenesis

    Cleavage activates SARM1. ( A ) Cell death–inducing activity of SARM1 truncations and caspase-3 cleaved fragments. SARM1 fragments, diagrammed on the left, were transiently transfected into HEK293T cells. Cell survival was measured 48 h later using the CellTiter-Glo Luminescent Cell Viability Assay. Percent cell survival was determined by normalization to control (EGFP expressing vector) transfection. Data are from three biological replicates. MLS, mitochondrial localization signal. ARM, armadillo repeats. SAM, sterile alpha motif. TIR, Toll, Interleukin 1 receptor, and Resistance protein domain. ( B ) The effect of SARM1 cleavage on the SARM1 NADase activity. Recombinant SARM1 (lacking its N-terminal 27 amino acids, i.e., SARM1 delta27) was incubated with active caspase-3 (1 unit) or control for 2 h at 37 °C. NADase activity was determined using the ε-NAD assay. AU, arbitrary units. Data are from three biological replicates. The cleavage of SARM1 delta27 was verified using a stain free gel. Stain free gel image was representative of three biological replicates. ( C ) Electroporation of PP triggers cell death of cells expressing engineered SARM1(with PP site, engineered EVLFNGP after D314) but not WT SARM1. EGFP, WT SARM1 or SARM1 PP expressing plasmids were transfected into HEK293T cells for 24 h, then control protein BSA or PP was electroporated into the cells. Percent cell survival was determined 20 h after electroporation by normalizing total ATP level to control electroporation. Data are from three biological replicates. ( D ) Electroporation of PP triggers the cleavage in HEK293T cells of engineered SARM1 containing a PP site (SARM1 PP) but not WT SARM1. SARM1 Western blot image was representative of three biological replicates. ( E ) Diagram of the findings. The caspase-3 cleavage site was determined by Edman degradation of the C-terminal fragment. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Caspase-3 cleaves and activates the NADase SARM1 to promote apoptosis, linking two cell death mechanisms

    doi: 10.1073/pnas.2528118123

    Figure Lengend Snippet: Cleavage activates SARM1. ( A ) Cell death–inducing activity of SARM1 truncations and caspase-3 cleaved fragments. SARM1 fragments, diagrammed on the left, were transiently transfected into HEK293T cells. Cell survival was measured 48 h later using the CellTiter-Glo Luminescent Cell Viability Assay. Percent cell survival was determined by normalization to control (EGFP expressing vector) transfection. Data are from three biological replicates. MLS, mitochondrial localization signal. ARM, armadillo repeats. SAM, sterile alpha motif. TIR, Toll, Interleukin 1 receptor, and Resistance protein domain. ( B ) The effect of SARM1 cleavage on the SARM1 NADase activity. Recombinant SARM1 (lacking its N-terminal 27 amino acids, i.e., SARM1 delta27) was incubated with active caspase-3 (1 unit) or control for 2 h at 37 °C. NADase activity was determined using the ε-NAD assay. AU, arbitrary units. Data are from three biological replicates. The cleavage of SARM1 delta27 was verified using a stain free gel. Stain free gel image was representative of three biological replicates. ( C ) Electroporation of PP triggers cell death of cells expressing engineered SARM1(with PP site, engineered EVLFNGP after D314) but not WT SARM1. EGFP, WT SARM1 or SARM1 PP expressing plasmids were transfected into HEK293T cells for 24 h, then control protein BSA or PP was electroporated into the cells. Percent cell survival was determined 20 h after electroporation by normalizing total ATP level to control electroporation. Data are from three biological replicates. ( D ) Electroporation of PP triggers the cleavage in HEK293T cells of engineered SARM1 containing a PP site (SARM1 PP) but not WT SARM1. SARM1 Western blot image was representative of three biological replicates. ( E ) Diagram of the findings. The caspase-3 cleavage site was determined by Edman degradation of the C-terminal fragment. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.

    Article Snippet: ABT-737 and the caspase inhibitor zVAD-FMK were purchased from Selleck Chemicals.

    Techniques: Activity Assay, Transfection, Cell Viability Assay, Control, Expressing, Plasmid Preparation, Sterility, Recombinant, Incubation, Staining, Electroporation, Western Blot

    Cleavage is required for SARM1 to promote apoptosis. ( A ) Generation of Sarm1 D314A KI mice. Diagram shows the intended SARM1 D314A allele. Sanger sequencing of PCR amplified DNA from Sarm1 D314A KI mice confirmed that D314 was successfully mutated to A . Additional same-sense mutations (marked with *) introduced by the KI strategy ( Methods ) were also confirmed. ( B ) SARM1 WT but not D314A is cleaved during apoptosis. Western blot of SARM1 from DRG cultures under different conditions shows that, unlike WT SARM1, SARM1 D314A is not cleaved. Cultures were treated with anti-NGF/anti-NGF+zVAD for 16 h or ABT-737 (10 µM) for 6 h. Data are representative of three independent experiments. ( C ) Effect of SARM1 D314A KI on primary macrophage apoptosis. Cells were treated with DMSO or TNF (10 ng/mL)+CHX (10 µg/mL) for 7 h. Data are from three biological replicates. ( D ) Effect of SARM1 D314A KI on primary T cell apoptosis. Cells were treated with DMSO or ABT-737 (1 µM) for 19 h. Data are from three biological replicates. ( E ) Effect of SARM1 D314A on DRG Wallerian degeneration. Cultures were imaged 6 h after axotomy. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( F ) Axon degeneration percentage of E was quantified and shown in the bar graphs. Data are from three biological replicates. ( G ) Effect of SARM1 D314A KI on axon degeneration induced by anti-NGF in the presence of caspase inhibitor. Cultures were imaged 20 h after being treated with DMSO, anti-NGF, or anti-NGF+zVAD. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( H ) Axon degeneration percentage of g was quantified and shown in the bar graphs. Data are from three biological replicates. ( I ) Schematic model illustrating caspase-dependent and -independent activation of SARM1. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Caspase-3 cleaves and activates the NADase SARM1 to promote apoptosis, linking two cell death mechanisms

    doi: 10.1073/pnas.2528118123

    Figure Lengend Snippet: Cleavage is required for SARM1 to promote apoptosis. ( A ) Generation of Sarm1 D314A KI mice. Diagram shows the intended SARM1 D314A allele. Sanger sequencing of PCR amplified DNA from Sarm1 D314A KI mice confirmed that D314 was successfully mutated to A . Additional same-sense mutations (marked with *) introduced by the KI strategy ( Methods ) were also confirmed. ( B ) SARM1 WT but not D314A is cleaved during apoptosis. Western blot of SARM1 from DRG cultures under different conditions shows that, unlike WT SARM1, SARM1 D314A is not cleaved. Cultures were treated with anti-NGF/anti-NGF+zVAD for 16 h or ABT-737 (10 µM) for 6 h. Data are representative of three independent experiments. ( C ) Effect of SARM1 D314A KI on primary macrophage apoptosis. Cells were treated with DMSO or TNF (10 ng/mL)+CHX (10 µg/mL) for 7 h. Data are from three biological replicates. ( D ) Effect of SARM1 D314A KI on primary T cell apoptosis. Cells were treated with DMSO or ABT-737 (1 µM) for 19 h. Data are from three biological replicates. ( E ) Effect of SARM1 D314A on DRG Wallerian degeneration. Cultures were imaged 6 h after axotomy. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( F ) Axon degeneration percentage of E was quantified and shown in the bar graphs. Data are from three biological replicates. ( G ) Effect of SARM1 D314A KI on axon degeneration induced by anti-NGF in the presence of caspase inhibitor. Cultures were imaged 20 h after being treated with DMSO, anti-NGF, or anti-NGF+zVAD. (Scale bar, 50 µm.) Images are representative of three independent experiments. ( H ) Axon degeneration percentage of g was quantified and shown in the bar graphs. Data are from three biological replicates. ( I ) Schematic model illustrating caspase-dependent and -independent activation of SARM1. In all panels, Student’s t test was used to determine statistical significance. * Indicates P < 0.05, NS, nonsignificant. Error bars represent SEM.

    Article Snippet: ABT-737 and the caspase inhibitor zVAD-FMK were purchased from Selleck Chemicals.

    Techniques: Sequencing, Amplification, Western Blot, Activation Assay